Assetmark, Inc Arrowhead Pharmaceuticals, Inc. Transaction History

Assetmark, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$25.16 - $41.38 $54,043 - $88,884	2,148 Added 3.8%	58,697 $2.09 Million
Q1 2023 May 05, 2023	SELL	$23.68 - $38.51 $649,210 - $1.06 Million	-27,416 Reduced 32.65%	56,549 $1.44 Million
Q4 2022 Feb 10, 2023	BUY	$28.0 - $40.56 $142,464 - $206,369	5,088 Added 6.45%	83,965 $3.41 Million
Q3 2022 Nov 01, 2022	BUY	$29.63 - $48.31 $279,144 - $455,128	9,421 Added 13.56%	78,877 $2.61 Million
Q2 2022 Aug 03, 2022	BUY	$27.79 - $50.61 $485,963 - $885,017	17,487 Added 33.65%	69,456 $2.45 Million
Q1 2022 May 13, 2022	BUY	$39.62 - $69.97 $957,377 - $1.69 Million	24,164 Added 86.91%	51,969 $2.39 Million
Q4 2021 Feb 14, 2022	BUY	$58.09 - $82.51 $1.54 Million - $2.18 Million	26,457 Added 1962.69%	27,805 $1.84 Million
Q3 2021 Nov 12, 2021	BUY	$58.38 - $84.96 $78,696 - $114,526	1,348 New	1,348 $84,000
Q3 2020 Nov 13, 2020	SELL	$33.21 - $51.27 $365 - $563	-11 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$20.56 - $63.12 $452 - $1,388	-22 Reduced 66.67%	11 $0
Q3 2019 Nov 13, 2019	BUY	$26.26 - $34.86 $866 - $1,150	33 New	33 $1,000

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.07B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.